Infliximab in severe steroid-refractory ulcerative colitis a pilot study

Only your doctor can recommend a course of treatment after checking your health condition. REMICADE ® (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those 65 years and older, have had serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE ® .

The active substance in Inflectra, infliximab, is a monoclonal antibody. A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) in the body. Infliximab has been designed to attach to a chemical messenger in the body called tumour necrosis factor alpha (TNF-alpha). This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Inflectra is used to treat. By blocking TNF-alpha, infliximab improves the inflammation and other symptoms of the diseases.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 10-Q and Form 8-K, all of which are filed with the . Securities and Exchange Commission and available at  and  .

Infliximab in severe steroid-refractory ulcerative colitis a pilot study

infliximab in severe steroid-refractory ulcerative colitis a pilot study

Media:

infliximab in severe steroid-refractory ulcerative colitis a pilot studyinfliximab in severe steroid-refractory ulcerative colitis a pilot studyinfliximab in severe steroid-refractory ulcerative colitis a pilot studyinfliximab in severe steroid-refractory ulcerative colitis a pilot studyinfliximab in severe steroid-refractory ulcerative colitis a pilot study

http://buy-steroids.org